Compare IBP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBP | GKOS |
|---|---|---|
| Founded | 1977 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 6.9B |
| IPO Year | 2014 | 2015 |
| Metric | IBP | GKOS |
|---|---|---|
| Price | $284.78 | $96.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $276.00 | $133.07 |
| AVG Volume (30 Days) | 320.2K | ★ 678.3K |
| Earning Date | 05-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ 6.70 | N/A |
| EPS | ★ 9.71 | N/A |
| Revenue | ★ $2,970,800,000.00 | $507,442,000.00 |
| Revenue This Year | $2.46 | $23.39 |
| Revenue Next Year | $4.53 | $27.46 |
| P/E Ratio | $27.98 | ★ N/A |
| Revenue Growth | 1.00 | ★ 32.33 |
| 52 Week Low | $150.83 | $73.16 |
| 52 Week High | $349.00 | $130.23 |
| Indicator | IBP | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 28.21 |
| Support Level | $254.83 | $93.96 |
| Resistance Level | $293.53 | $97.00 |
| Average True Range (ATR) | 14.57 | 3.77 |
| MACD | -6.19 | -2.37 |
| Stochastic Oscillator | 19.86 | 1.28 |
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.